Abstract
Cigarette smoke, a toxic collection of thousands of chemicals generated from combustion of tobacco, is recognized as the primary causative agent of certain diffuse interstitial and bronchiolar lung diseases. Most patients afflicted with these disorders are cigarette smokers, and smoking cessation has been shown to be capable of inducing disease remission and should occupy a pivotal role in the management of all smokers with these diffuse lung diseases. The role of pharmacotherapy with corticosteroids or other immunomodulating agents is not well established but may be considered in patients with progressive forms of smoking-related interstitial lung diseases.
Copyright © 2012 Elsevier Inc. All rights reserved.
MeSH terms
-
Acute Disease
-
Bronchiolitis / diagnosis
-
Bronchiolitis / etiology
-
Chronic Disease
-
Diagnosis, Differential
-
Histiocytosis, Langerhans-Cell / diagnosis
-
Histiocytosis, Langerhans-Cell / etiology
-
Humans
-
Lung / diagnostic imaging*
-
Lung / pathology*
-
Lung / physiopathology
-
Lung Diseases, Interstitial / classification
-
Lung Diseases, Interstitial / diagnosis*
-
Lung Diseases, Interstitial / diagnostic imaging
-
Lung Diseases, Interstitial / etiology*
-
Lung Diseases, Interstitial / pathology
-
Lung Diseases, Interstitial / physiopathology
-
Pulmonary Alveolar Proteinosis / diagnosis
-
Pulmonary Alveolar Proteinosis / etiology
-
Pulmonary Eosinophilia / diagnosis
-
Pulmonary Eosinophilia / etiology
-
Pulmonary Fibrosis / diagnosis
-
Pulmonary Fibrosis / etiology
-
Pulmonary Surfactant-Associated Protein C / deficiency
-
Smoking / adverse effects*
-
Tomography, X-Ray Computed
Substances
-
Pulmonary Surfactant-Associated Protein C
Supplementary concepts
-
Surfactant Metabolism Dysfunction, Pulmonary, 2